New shot aims to silence hepatitis b virus for good

NCT ID NCT07370207

Recruiting now Disease control Sponsor: AusperBio Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated May 13, 2026 · Updated 15 times

Summary

This study tests an experimental drug called AHB-137 in adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the injection can lower the virus to undetectable levels and allow patients to stop all hepatitis B medications. About 84 people in the Asia Pacific region will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Asan Medical Center
NOT_YET_RECRUITING

Seoul, 05505, South Korea
Chiayi Christian Hospital
NOT_YET_RECRUITING

Chiayi City, 60002, Taiwan
E-DA Hospital
NOT_YET_RECRUITING

Kaohsiung City, 82445, Taiwan
National Taiwan University Hospital
NOT_YET_RECRUITING

Taipei, 100, Taiwan
National University Hospital - Singapore
NOT_YET_RECRUITING

Singapore, 119074, Singapore
New Zealand Clinical Research
RECRUITING

Grafton, Auckland, 1010, New Zealand
Queen Mary Hospital - PPDS
NOT_YET_RECRUITING

Hong Kong, China
St Vincents Hospital Melbourne
NOT_YET_RECRUITING

Fitzroy, Victoria, 3065, Australia

Conditions

Explore the condition pages connected to this study.

HEPATITIS B, CHRONIC